Companies / ALX Oncology Holdings Inc. / Activity
Activity — ALX Oncology Holdings Inc.
16 moves.
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Goodman Corey S Director | Buy | Common Stock | $5.00M | +3.2M +60.45% | 8,453,038 6.11% of shares | high |
| Mar 19, 2026 | Lettmann Jason CEO | Sell | Common Stock | $26.7K | -12K -4.02% | 293,609 0.21% of shares | low |
| Feb 17, 2026 | Lettmann Jason CEO | Other | Common Stock | $5.0K | -2K -0.71% | 305,920 0.22% of shares | low |
| Jan 6, 2026 | Pinto Shelly Executive | Sell | Common Stock | $4.4K | -4K -4.26% | 88,273 0.06% of shares | low |
| Mar 19, 2026 | Pinto Shelly Executive | Sell | Common Stock | $2.0K | -903 -1.03% | 86,805 0.06% of shares | low |
| Feb 18, 2026 | Pinto Shelly Executive | Sell | Common Stock | $1.3K | -565 -0.64% | 87,708 0.06% of shares | low |
| Jan 20, 2026 | Sandler Alan B. Director | Grant | Stock option (right to buy) | — | +10K | 10,100 <0.01% of shares | low |
| Mar 3, 2026 | Klencke Barbara Executive | Grant | Stock option (right to buy) | — | +700K | 700,000 0.51% of shares | low |
| Jan 26, 2026 | Shantharam Harish Executive | Grant | Stock option (right to buy) | — | +303K | 303,000 0.22% of shares | low |
| Jan 26, 2026 | Pinto Shelly Executive | Grant | Stock option (right to buy) | — | +192K | 192,000 0.14% of shares | low |
| Jan 26, 2026 | Lettmann Jason CEO | Grant | Stock option (right to buy) | — | +912K | 912,000 0.66% of shares | low |
| Jan 20, 2026 | Goodman Corey S Director | Grant | Stock Option (right to buy) | — | +40K | 40,400 0.03% of shares | low |
| Jan 20, 2026 | Garland J. Scott Director | Grant | Stock option (right to buy) | — | +40K | 40,400 0.03% of shares | low |
| Jan 20, 2026 | Curran Daniel J. Director | Grant | Stock Option (right to buy) | — | +17K | 16,833 0.01% of shares | low |
| Jan 20, 2026 | Takimoto Chris H Director | Grant | Stock option (right to buy) | — | +40K | 40,400 0.03% of shares | low |
| Jan 20, 2026 | Hemrajani Rekha Director | Grant | Stock option (right to buy) | — | +40K | 40,400 0.03% of shares | low |